Welcome To The Equinox Minerals HUB On AGORACOM
Copper and Uranium mine in S. Africa
  • Demo Video
  • Private Messages
  • Edit My Profile
  • View/Edit Portfolio

AGORACOM News Flash

AGORACOM WIRE - FRIDAY MAY 25TH, 2012

FOCUS METALS (TSXV:FMS) Changes Its Name to Focus Graphite Inc.

  • Aim to develop and manufacture the best technology graphite in the world
  • Additional shareholder value will come from investment in commercialized graphene through joint venture partner, Grafoid Inc.

Read More   |   *SPONSOR

INTERNATIONAL PBX VENTURES (TSX:PBX) Signs Copaquire Joint Venture Option Agreement - $90M Potential Payment Read More

AGORACOM Maintenance Alert: Friday Evening Downtime for About an Hour Read More

LOMIKO METALS (TSXV:LMR) Graphite and Zinc Price Outlook is Favourable Through 2013  Read More   |   *SPONSOR

 

 

Message: Classic slugfest take shape with Lundin

Fall_walk_oct05_012
Rank: [?]
President
Points: [?]
32329
Rating: [?]
Votes: 245 Score: 3.6
  • Currently 3.7/5 Stars.
Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.

Classic slugfest take shape with Lundin

posted on Mar 30, 11 07:42AM

Michael Babad
RTGAM


Lundin v. Equinox

Analysts are taking a fresh look today at the scenarios for Lundin Mining Corp. after it called off its friendly merger with Inmet Mining Corp. late yesterday, and set in motion a new auction.

The death of the deal to create a Canadian copper giant paves the way for a hostile move by Equinox Minerals Ltd. , which is offering $4.8-billion. Lundin has rejected that, and says it will continue to fight.

UBS Securities Canada analyst today boosted the 12-month price target on Lundin stock to $8.90 from $8.10. Here's how UBS sees it: A 40-per-cent chance of drumming up rival bids at an estimated price of $10.40 a share, a 50-per-cent probability of a successful Equinox bid at $8.10 a share, and a 10-per-cent chance of no deal, which would put the stock at $6.70.

"We therefore raise our target by 10 per cent to $8.90 and maintain a Buy rating, while highlighting the relatively short window of opportunity for [Lundin]."

UBS also believes Equinox could legally challenge Lundin's 11th-hour poison pill.

New Message

Please login to post a reply

AGORACOM Quick Tips

Small-Cap CEO Lessons - Is Your CEO Out Of Touch? ... Not Anymore

President's D.D.

New feature: Hub Presidents can add important links here.